Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03478553 · ClinicalTrials.gov registry record
The Genetics of Pulmonary Fibrosis
A clinical trial of Idiopathic Pulmonary Fibrosis (IPF), sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT03478553: Recruiting study of Idiopathic Pulmonary Fibrosis (IPF), sponsored by University of Colorado, Denver.
NCT03478553 is a study of Idiopathic Pulmonary Fibrosis (IPF) that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 1,000 participants, above the 372-participant average among 8 other Idiopathic Pulmonary Fibrosis (IPF) trials with a reported enrollment target (169% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03478553, a study of Idiopathic Pulmonary Fibrosis (IPF), is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This study seeks to screen first degree family members of people with Idiopathic Pulmonary Fibrosis (IPF) for the earliest signs of lung fibrosis.
Primary Outcome
The investigators aim is to identify and explore genetic loci that affect development of pulmonary fibrosis and also explore related environmental exposures. Idiopathic pulmonary fibrosis (IPF) is one of the interstitial lung diseases under the broader umbrella of idiopathic interstitial pneumonias (IIP). The investigators hypothesize that inherited genetic factors are associated with pulmonary fibrosis.
Conditions Studied
Interventions
- OTHER Blood draw
- OTHER Questionnaire
Study Locations (1)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2018-01-18 |
| Est. Completion | 2026-12-31 |
What NCT03478553 shows while recruiting
NCT03478553 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 372-participant average among 8 other Idiopathic Pulmonary Fibrosis (IPF) trials with a reported enrollment target (169% higher).
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis (IPF) appearing as the primary indexed condition, and to 2 interventions - of which Blood draw is the first listed.
NCT03478553 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT03478553 about?
NCT03478553 is a clinical study titled "The Genetics of Pulmonary Fibrosis". This study seeks to screen first degree family members of people with Idiopathic Pulmonary Fibrosis (IPF) for the earliest signs of lung fibrosis.
What is the current status of trial NCT03478553?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2018-01-18. Estimated completion is 2026-12-31.
What conditions does trial NCT03478553 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis (IPF).
What interventions are being tested in trial NCT03478553?
The interventions under investigation include: Blood draw (OTHER), Questionnaire (OTHER).
Who is sponsoring clinical trial NCT03478553?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03478553 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis (IPF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03478553's enrollment target sits among peer trials
1,000 2nd of 8 the highest of 8 other Idiopathic Pulmonary Fibrosis (IPF) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis (IPF) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
RECRUITING
-
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
RECRUITING · Phase 2
-
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
RECRUITING · Phase 2
-
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 1
-
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI